Cartesian Growth Corporation II
Cartesian Growth Corporation II Fundamental Analysis
Cartesian Growth Corporation II (RENEF) shows weak financial fundamentals with a PE ratio of 38.24, profit margin of 0.00%, and ROE of -4.28%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 19.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze RENEF's fundamental strength across five key dimensions:
Efficiency Score
WeakRENEF struggles to generate sufficient returns from assets.
Valuation Score
ModerateRENEF shows balanced valuation metrics.
Growth Score
WeakRENEF faces weak or negative growth trends.
Financial Health Score
ModerateRENEF shows balanced financial health with some risks.
Profitability Score
WeakRENEF struggles to sustain strong margins.
Key Financial Metrics
Is RENEF Expensive or Cheap?
P/E Ratio
RENEF trades at 38.24 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, RENEF's PEG of -0.16 indicates potential undervaluation.
Price to Book
The market values Cartesian Growth Corporation II at -1.67 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -213.25 times EBITDA. This is generally considered low.
How Well Does RENEF Make Money?
Net Profit Margin
For every $100 in sales, Cartesian Growth Corporation II keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-4.28 in profit for every $100 of shareholder equity.
ROA
Cartesian Growth Corporation II generates $2.66 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.22 in free cash annually.
FCF Yield
RENEF converts -0.41% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
38.24
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.16
vs 25 benchmark
P/B Ratio
Price to book value ratio
-1.67
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.04
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.04
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
-0.03
vs 25 benchmark
How RENEF Stacks Against Its Sector Peers
| Metric | RENEF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 38.24 | 19.12 | Worse (Expensive) |
| ROE | -4.28% | 806.00% | Weak |
| Net Margin | 0.00% | -7537.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 1.00 | Strong (Low Leverage) |
| Current Ratio | 0.04 | 612.42 | Weak Liquidity |
| ROA | 2.66% | -21090.00% (disorted) | Weak |
RENEF outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cartesian Growth Corporation II's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical